People are still getting sick, but you might not know it by looking at the peaked complexion of most health care companies these days. A weak implantable cardioverter defibrillators (ICD) market has knee-capped names like Medtronic (NYSE:MDT) and St. Jude (NYSE:STJ), weak procedure volume growth has hampered Covidien (NYSE:COV) and Bard (NYSE:BCR) and weak trends in orthopedics and surgery has hurt both Johnson & Johnson (NYSE:JNJ) and Stryker (NYSE:SYK).
In the case of Stryker, this is an especially painful reminder that the good ol' days when Stryker reliably posted 20% growth are long past. Stryker is doing better than most, and has a brighter outlook than most of its peers, but it can be difficult to get a stock moving when reported growth is so sluggish.
Click below for the full piece:
http://stocks.investopedia.com/stock-analysis/2011/Stryker-Scraping-By-SYK-JNJ-ZMH-COV-NUVA-ISRG-MDT1024.aspx
No comments:
Post a Comment